Skip to main content

New story in Health from Time: Johnson & Johnson Ending Sales of Talcum Powder Products in U.S.



Johnson & Johnson discontinued its legacy talc-based baby-powder products in the U.S. and Canada after thousands of suits alleging asbestos contamination led to a decline in sales.

The health-care giant said Tuesday it had stopped shipping hundreds of talc-based items in the U.S. and Canada after coming to a “commercial decision” to discontinue them. J&J will wind down sales in those markets over the coming months, said Kathleen Widmer, chairman of the company’s North America consumer unit. All existing inventory will continue to be sold through retailers until supplies run out, she said. J&J first began selling baby-powder products in the 1890s, according to a company blog.

J&J has faced lawsuits accusing it of hiding the cancer risks tied its talc-based version of baby powder since 2014. Juries across the U.S. have hit the company with billions of dollars in actual and punishment damages over their handling of the product. J&J has been successful in getting many of those verdicts reduced or wiped out on appeal.

Shares of the New Brunswick, New Jersey-based company declined 0.3% in late trading to $148.55. Since the start of this year, the shares had gained 2.2% through Tuesday’s close.

Read more: Johnson & Johnson Is Just the Tip of the Toxic Iceberg

J&J’s cornstarch-based baby powder, which has been on the market since 1980, will continue to be sold in the U.S. and Canada. Widmer said 75% of its U.S. baby-power customers use the cornstach product, while 25% rely on the talc-based product. Outside the U.S. those numbers are reversed, Widmer said, and the talc-based product will continue to be distributed abroad.

Johnson’s Baby Powder currently accounts for less than 1% of the company’s U.S. consumer-health revenue. It has seen a 60% decline in sales since 2017 as consumer habits have changed, Widmer said. The company blames “misinformation around the safety of the product and a constant barrage of litigation advertising” for the drop in demand, according to a statement.

“We’re not in the business of confusing customers,” Widmer said.

The decision to discontinue was made during a portfolio assessment related to Covid-19 in March.

“We needed to skinny down” to free up space in manufacturing plants to allow for appropriate social distancing, Widmer said. “We probably would have waited a couple of months otherwise. But we knew the business, which is already small in scale, would continue to decline.”

Talcum powder has long been a mainstay of baby products because the mineral keeps skin dry and prevents diaper rash. Talc mines, however, can also yield asbestos, a mineral once used in products such as building insulation. Some companies have found corn starch can offer the same benefits of talc without the asbestos risk.

In October, J&J said it would pull a single lot of 33,000 bottles off the market after a Food and Drug Administration-conducted test uncovered tiny amounts of the contaminant in one bottle of baby powder. But the company said lab tests it commissioned found no sign of asbestos in the recalled lot, putting it at odds with U.S. health regulators who stuck by their test results.

The standoff occurred as lawsuits against the company continued to climb. J&J officials said last month they’d had a 15% increase in the number of suits alleging baby powder causes different kinds of cancer. Discontinuing its talc-based baby powder in the U.S. could limit the number of cancer lawsuits the 127-year-old product generates each year.

J&J is likely seeking an “end date for talc claims,” said Leigh O’Dell, an Alabama-based lawyer who is overseeing more than 16,000 suits in federal court in New Jersey blaming the product for causing ovarian cancer. The move to discontinue sales “puts a fence around the litigation for them.”

Last year, Bausch Health Cos., maker of Shower to Shower powder, said it reformulated the product to replace talc with corn starch as the active ingredient. The firm hadn’t disclosed the switch until Bloomberg News asked about it.

J&J previously owned Shower to Shower but sold it to Bausch predecessor Valeant Pharmaceuticals International.

Johnson & Johnson “remains steadfastly confident in the safety of talc-based Johnson’s Baby Powder,” the company said in a statement. “We will continue to vigorously defend the product, its safety, and the unfounded allegations against it and the company in the courtroom.”

Popular posts from this blog

New story in Health from Time: Here’s How Quickly Coronavirus Is Spreading in Your State

The novel coronavirus pandemic is a global crisis, a national emergency and a local nightmare. But while a great deal of the focus in the U.S. has been on the federal government’s response, widely criticized as slow and halting , the picture on the ground remains very different in different parts of the country. A TIME analysis of the per capita spread of the epidemic in all 50 states and Washington, D.C. found considerable range in the rate of contagion, and, in some parts of the country, a significant disparity compared to the national figure. The U.S., unlike nations such as South Korea and now Italy , has yet to show signs of bringing the runaway spread of the virus under control. However, while no single state is yet showing strong signs of bending the curve , some are faring much worse than others. The following graphic plots the rise in the total confirmed cases of COVID-19 per 100,000 residents in each state, plotted by the day that each state reported its first case.

New story in Health from Time: We Need to Take Care of the Growing Number of Long-term COVID-19 Patients

On July 7, 2020, the Boston Red Sox pitcher Eduardo Rodriguez tested positive for the new coronavirus. He was scheduled to start Opening Day for the Sox, but the virus had other plans— damaging Rodriguez’s heart and causing a condition called myocarditis (inflammation of the heart muscle). Now the previously fit 27-year old ace left-hander must sit out the 2020 season to recover. Rodriguez is not alone in having heart damage from SARS-CoV-2, the virus that causes COVID-19. In a new study done in Germany, researchers studied the hearts of 100 patients who had recently recovered from COVID-19. The findings were alarming: 78 patients had heart abnormalities, as shown by a special kind of imaging test that shows the heart’s structure (a cardiac MRI), and 60 had myocarditis. These patients were mostly young and previously healthy . Several had just returned from ski trips. While other studies have shown a lower rate of heart problems—for example, a study of 416 patients hosp

New story in Health from Time: What We Don’t Know About COVID-19 Can Hurt Us

Countries around the world have introduced stringent control measures to stop COVID-19 outbreaks growing, but now many find themselves facing the same situation again. From Melbourne to Miami, the relaxation of measures had led to increasing flare-ups, which in some places has already meant reclosing schools, businesses or travel routes. Within the U.S. and among different countries , places with wildly varying public-health policies have experienced wildly diverse outcomes. Most ominously, infections are rising rapidly in many places where they once were falling. So how do countries avoid an indefinite, unsustainable, cycle of opening and closing society? What is needed to prevent a future of strict social distancing and closed borders? To escape this limbo, we need to know more about each step in the chain of infection: why some people are more susceptible or have more symptoms, how our interactions and surroundings influence risk, and how we can curb the impact of the re